BNC Korea botulinum toxin ‘Vienox Injection’ sold domestically
Vienox Injection obtained approval from the Ministry of Food and Drug Safety in March
Botulinum toxin produced with the latest equipment and processes
Dongkook Pharmaceutical strengthens medical aesthetics portfolio
Dongkook Pharmaceutical joins hands with a new botulinum toxin company to strengthen its presence in the domestic skin care, plastic surgery, and treatment markets.
Dongkook Pharmaceutical announced on the 18th that it signed an exclusive domestic sales contract with BNC Korea for the botulinum toxin preparation ‘Vienox Injection’. The contract was signed on the 16th at Dongkuk Pharmaceutical’s headquarters in Cheongdam-dong, Gangnam-gu, Seoul.
According to the contract, Dongkook Pharmaceutical and B&C Korea will jointly discover new customers and conduct marketing for Vienox Injection. Botulinum toxin is effective in preventing or improving wrinkles by temporarily paralyzing muscles by inhibiting neurotransmitters at nerve endings.
In the case of Korea BNC Bienox Injection, domestic approval was obtained from the Ministry of Food and Drug Safety (MFDS) in March this year for its efficacy in temporarily improving moderate to severe glabellar wrinkles related to the activity of the corrugator and procerus muscles. . The main advantage of Vienox is said to be the latest equipment for producing botulinum toxin. BNC Korea explained that the reduced-pressure drying method was applied to shorten the process time and minimize protein damage. Product safety and effectiveness were proven through clinical trials conducted domestically.
A Dongkuk Pharmaceutical official said, “We expect that this domestic exclusive distribution contract will allow Dongkuk Pharmaceutical to further specialize its medical esthetic business,” adding, “The brand value and awareness of Vienox will increase, and it will also have the effect of enhancing trust between doctors and patients.” “We will do our best to maximize the synergy between the two companies.”
Dongkuk Pharmaceutical, based on its research and development know-how on the HA filler product ‘Blast’ that has been used consistently for 13 years, has developed a new HA filler ‘Cablelyn’, skin booster ‘Dhive’, and wound dressing ‘Madeca MD Cream and Lotion’. ‘ and various other products were introduced. In addition, through cooperation with BNC Korea, the product portfolio has been expanded to include botulinum toxin preparations. In line with strengthening the portfolio, the company plans to accelerate its efforts to target the domestic skin care and plastic surgery market.
B&C Korea is a company that has exported botulinum toxin to over 40 countries since 2020. We are engaged in the business of supplying botulinum toxin preparations, starting with medical devices for cosmetic surgery and surgery and procedures. In 2019, it was successfully listed on KOSDAQ. Domestic approval for botulinum toxin products was received in March. The plan is to solidify its position in the domestic market through this copyright agreement.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog